{"id":"NCT02806986","sponsor":"Grifols Therapeutics LLC","briefTitle":"Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency","officialTitle":"A Multi-Center, Open-Label, Single-Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06","primaryCompletion":"2019-05-15","completion":"2019-05-15","firstPosted":"2016-06-21","resultsPosted":"2020-06-16","lastUpdate":"2020-06-16"},"enrollment":61,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immunodeficiency"],"interventions":[{"type":"BIOLOGICAL","name":"IGSC 20%","otherNames":["Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography"]}],"arms":[{"label":"IGSC 20%","type":"EXPERIMENTAL"}],"summary":"Approximately 60 subjects will be enrolled in order to have approximately 20 adult subjects and 20 pediatric subjects treated with subcutaneously administered Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (IGSC 20%) who complete the entire study. This study will include 3 study stages: Screening/Previous Regimen Phase, IGSC 20% Treatment Stage 1 (13 IGSC 20% weekly doses), and IGSC 20% Treatment Stage 2 (39 IGSC 20% weekly doses). A total of 52 doses of IGSC 20% will be administered with a final follow-up visit 1 week after the last dose at Week 53. Subjects/caregivers will be trained on self-administration of IGSC 20% by the clinical site personnel.","primaryOutcome":{"measure":"Rate of Serious Bacterial Infection (SBI) Per Participant Per Year","timeFrame":"IGSC 20% Treatment Stage 1: Week 1 to 13; IGSC 20% Treatment Stage 2: Week 14 to 53; IGSC 20% Overall: Week 1 to 53","effectByArm":[{"arm":"IGSC 20% Treatment Stage 1","deltaMin":0,"sd":null},{"arm":"IGSC 20% Treatment Stage 2","deltaMin":0.023,"sd":null},{"arm":"IGSC 20% Overall","deltaMin":0.017,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":23,"countries":["Australia","Czechia","France","Germany","Hungary","Poland","Spain","Sweden","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":61},"commonTop":["Nasopharyngitis","Infusion site erythema","Cough","Upper respiratory tract infection","Infusion site pruritus"]}}